PRMT1 inhibitors and uses thereof

• US 9,475,776 B2
• Filed: 04/01/2015
• Issued: 10/25/2016
• Est. Priority Date: 03/14/2013
• Status: Active Grant

• Current Assignee: Epizyme, Inc. (Ipsen Sa)
• Original Assignee: Epizyme, Inc. (Ipsen Sa)
• Inventors: Kuntz, Kevin Wayne, Mitchell, Lorna Helen, Shapiro, Gideon, Chesworth, Richard, Boriack-Sjodin, Paula Ann
• Primary Examiner(s): BARKER, MICHAEL P
• Application Number:
  US14/675,781
• Publication Number:
  US 20150284334A1
• Time in Patent Office: 573 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07D 231/12 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.

Claims

1. A method of treating a PRMT1-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:

2. The method of claim 1, wherein the PRMT1-mediated disorder is a proliferative disorder.

3. The method of claim 2, wherein the proliferative disorder is cancer.

4. The method of claim 1, wherein the PRMT1-mediated disorder is a neurological disorder.

5. The method of claim 4, wherein the neurological disorder is amyotrophic lateral sclerosis.

6. The method of claim 1, wherein the PRMT1-mediated disorder is a muscular dystrophy.

7. The method of claim 1, wherein the PRMT1-mediated disorder is an autoimmune disorder.

8. The method of claim 1, wherein the PRMT1-mediated disorder is a vascular disorder.

9. The method of claim 1, wherein the PRMT1-mediated disorder is a metabolic disorder.